



RECEIVED

OCT 17 2002

Docket No.: 203975US0X

TECH CENTER 1600/2900

165

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

VINCENT K. SHIER, PH.D.
REGISTERED PATENT AGENT
(703) 413-3000
VSHIER@OBLON.COM

RE: Application Serial No.: 09/903,771

Applicants: Bettina MOECKEL, et al.

Filing Date: July 13, 2001

For: NUCLEOTIDE SEQUENCES CODING FOR THE
LUXR GENE

Group Art Unit: 1652

Examiner: Kathleen M. KERR

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Vincent K. Shier, Ph.D.
Registration No. 50,552

DOCKET NO.: 203975US0X



#8/jrm
10-17-02

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Bettina MOECKEL, et al.

: GROUP ART UNIT: 1652

RECEIVED

OCT 17 2002

SERIAL NO.: 09/903,771

:

FILED: JULY 13, 2001

: EXAMINER: KERR

TECH CENTER 1600/2900

FOR: NUCLEOTIDE SEQUENCES WHICH CODE FOR THE luxR GENE

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated September 19, 2002, Applicants elect, with traverse, Group I, Claims 1-19 and 37-38, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

- Group I: Claims 1-19 and 37-38, drawn to polynucleotides encoding a luxR transcriptional activation gene, vectors, host cells, and methods of making a luxR protein;
- Group II: Claims 20-21, drawn to Corynebacterium with an attenuated luxR gene;
- Group III: Claim 22, drawn to E. coli with a plasmid containing an attenuated luxR gene;
- Group IV: Claims 23-30, drawn to methods for making amino acids;
- Group V: Claims 31-36, drawn to hybridization methods; and
- Group VI: Claim 39, drawn to a luxR protein.